Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 288

1.

Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested.

Grayston JT, Belland RJ, Byrne GI, Kuo CC, Schachter J, Stamm WE, Zhong G.

Pathog Dis. 2015 Feb;73(1):1-9. doi: 10.1093/femspd/ftu015. Epub 2014 Dec 4. Review. No abstract available.

2.

Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome.

Cannon CP, Braunwald E, McCabe CH, Grayston JT, Muhlestein B, Giugliano RP, Cairns R, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators.

N Engl J Med. 2005 Apr 21;352(16):1646-54.

3.

Azithromycin for the secondary prevention of coronary events.

Grayston JT, Kronmal RA, Jackson LA, Parisi AF, Muhlestein JB, Cohen JD, Rogers WJ, Crouse JR, Borrowdale SL, Schron E, Knirsch C; ACES Investigators.

N Engl J Med. 2005 Apr 21;352(16):1637-45.

4.

Chlamydia pneumoniae and atherosclerosis.

Grayston JT.

Clin Infect Dis. 2005 Apr 15;40(8):1131-2. Epub 2005 Mar 14. No abstract available.

PMID:
15791512
5.

Effect of short-term antibiotic treatment on Chlamydia pneumoniae and peripheral endothelial function.

Kuvin JT, Gokce N, Holbrook M, Hunter LM, Patel AR, Sliney KA, Craven DE, Grayston JT, Keaney JF Jr, Karas RH, Vita JA.

Am J Cardiol. 2003 Mar 15;91(6):732-5. No abstract available.

PMID:
12633811
6.

Antibiotic treatment of atherosclerotic cardiovascular disease.

Grayston JT.

Circulation. 2003 Mar 11;107(9):1228-30. No abstract available.

PMID:
12628937
7.

Preclinical models for Chlamydia pneumoniae and cardiovascular disease: hypercholesterolemic mice.

Campbell LA, Moazed TC, Kuo CC, Grayston JT.

Clin Microbiol Infect. 1998 Jan;4 Suppl 4:S23-S32.

8.

Radical changes to chlamydial taxonomy are not necessary just yet.

Schachter J, Stephens RS, Timms P, Kuo C, Bavoil PM, Birkelund S, Boman J, Caldwell H, Campbell LA, Chernesky M, Christiansen G, Clarke IN, Gaydos C, Grayston JT, Hackstadt T, Hsia R, Kaltenboeck B, Leinonnen M, Ojcius D, McClarty G, Orfila J, Peeling R, Puolakkainen M, Quinn TC, Rank RG, Raulston J, Ridgeway GL, Saikku P, Stamm WE, Taylor-Robinson DT, Wang SP, Wyrick PB.

Int J Syst Evol Microbiol. 2001 Jan;51(Pt 1):249; author reply 251-3. No abstract available. Erratum in: Int J Syst Evol Microbiol. 2006 Mar;56(Pt 3):677. Ocjius, D [corrected to Ojcius, D].

PMID:
11211265
9.

Association between C-reactive protein, anti-Chlamydia pneumoniae antibodies, and vascular function in healthy adults.

Sharma N, Rutherford JD, Grayston JT, King LP, Jialal I, Andrews TC.

Am J Cardiol. 2001 Jan 1;87(1):119-21, A9.

PMID:
11137849
10.

Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer.

Jackson LA, Wang SP, Nazar-Stewart V, Grayston JT, Vaughan TL.

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1263-6.

11.

Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults : the Cardiovascular Health Study.

Siscovick DS, Schwartz SM, Corey L, Grayston JT, Ashley R, Wang SP, Psaty BM, Tracy RP, Kuller LH, Kronmal RA.

Circulation. 2000 Nov 7;102(19):2335-40.

PMID:
11067785
12.

Secondary prevention antibiotic treatment trials for coronary artery disease.

Grayston JT.

Circulation. 2000 Oct 10;102(15):1742-3. No abstract available.

PMID:
11023925
13.
14.

Chlamydia pneumoniae and the risk of first ischemic stroke : The Northern Manhattan Stroke Study.

Elkind MS, Lin IF, Grayston JT, Sacco RL.

Stroke. 2000 Jul;31(7):1521-5.

PMID:
10884447
15.

What is needed to prove that Chlamydia pneumoniae does, or does not, play an etiologic role in atherosclerosis?

Grayston JT.

J Infect Dis. 2000 Jun;181 Suppl 3:S585-6. No abstract available.

PMID:
10839765
16.

Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction.

Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM.

J Infect Dis. 2000 Jun;181 Suppl 3:S563-5.

PMID:
10839759
17.

Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma.

Jackson LA, Campbell LA, Schmidt RA, Kuo C, Cappuccio AL, Lee MJ, Grayston JT.

J Infect Dis. 2000 Jun;181 Suppl 3:S447-8.

PMID:
10839735
18.

Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results.

Peeling RW, Wang SP, Grayston JT, Blasi F, Boman J, Clad A, Freidank H, Gaydos CA, Gnarpe J, Hagiwara T, Jones RB, Orfila J, Persson K, Puolakkainen M, Saikku P, Schachter J.

J Infect Dis. 2000 Jun;181 Suppl 3:S426-9.

PMID:
10839729
19.

Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology.

Siscovick DS, Schwartz SM, Caps M, Wang SP, Grayston JT.

J Infect Dis. 2000 Jun;181 Suppl 3:S417-20. Review.

PMID:
10839727
20.

Background and current knowledge of Chlamydia pneumoniae and atherosclerosis.

Grayston JT.

J Infect Dis. 2000 Jun;181 Suppl 3:S402-10. Review.

PMID:
10839724
21.

Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial.

Vergis EN, Indorf A, File TM Jr, Phillips J, Bates J, Tan J, Sarosi GA, Grayston JT, Summersgill J, YU VL.

Arch Intern Med. 2000 May 8;160(9):1294-300.

PMID:
10809032
22.

Design of future intervention studies for Chlamydia pneumoniae in atherosclerosis.

Grayston JT.

Am Heart J. 1999 Nov;138(5 Pt 2):S556-7. Review. No abstract available.

PMID:
10539875
23.

Secondary prevention trials for coronary artery disease with antibiotic treatment for Chlamydia pneumoniae: design issues.

Grayston JT, Jackson LA, Kennedy WJ, Kronmal RA.

Am Heart J. 1999 Nov;138(5 Pt 2):S545-9. Review. No abstract available.

PMID:
10539871
24.

Safety and effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease.

Jackson LA, Stewart DK, Wang SP, Cooke DB, Cantrell T, Grayston JT.

J Antimicrob Chemother. 1999 Sep;44(3):411-4.

PMID:
10511413
25.

Does Chlamydia pneumoniae cause atherosclerosis?

Grayston JT.

Arch Surg. 1999 Sep;134(9):930-4. Review. No abstract available.

PMID:
10487585
26.

Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae.

Zhou YF, Csako G, Grayston JT, Wang SP, Yu ZX, Shou M, Leon M, Epstein SE.

Am J Cardiol. 1999 Sep 1;84(5):595-8, A8.

PMID:
10482163
27.

The role of Chlamydia pneumoniae in atherosclerosis.

Grayston JT, Campbell LA.

Clin Infect Dis. 1999 May;28(5):993-4. No abstract available.

PMID:
10452623
28.

Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study.

Nieto FJ, Folsom AR, Sorlie PD, Grayston JT, Wang SP, Chambless LE.

Am J Epidemiol. 1999 Jul 15;150(2):149-56.

PMID:
10412959
29.

Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice.

Moazed TC, Campbell LA, Rosenfeld ME, Grayston JT, Kuo CC.

J Infect Dis. 1999 Jul;180(1):238-41.

PMID:
10353889
30.

Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline.

Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM.

Emerg Infect Dis. 1999 Mar-Apr;5(2):281-4.

31.

Antibiotic treatment trials for secondary prevention of coronary artery disease events.

Grayston JT.

Circulation. 1999 Mar 30;99(12):1538-9. No abstract available.

PMID:
10096927
32.

Chlamydia pneumoniae and cardiovascular disease.

Campbell LA, Kuo CC, Grayston JT.

Emerg Infect Dis. 1998 Oct-Dec;4(4):571-9. Review.

33.

Role of chlamydia pneumoniae (TWAR) in IgA nephropathy.

Chen M, Schena FP, Wang SP, Grayston JT, Johnson RJ.

Nephron. 1998 Sep;80(1):92. No abstract available.

PMID:
9730716
34.

Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis.

Davidson M, Kuo CC, Middaugh JP, Campbell LA, Wang SP, Newman WP 3rd, Finley JC, Grayston JT.

Circulation. 1998 Aug 18;98(7):628-33.

PMID:
9715854
35.

Evidence of systemic dissemination of Chlamydia pneumoniae via macrophages in the mouse.

Moazed TC, Kuo CC, Grayston JT, Campbell LA.

J Infect Dis. 1998 May;177(5):1322-5.

PMID:
9593019
36.

Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events.

Grayston JT.

Circulation. 1998 May 5;97(17):1669-70. No abstract available.

PMID:
9591758
37.

Chlamydia pneumoniae and cardiovascular disease.

Grayston JT, Kuo CC, Campbell LA, Wang SP, Jackson LA.

Cardiologia. 1997 Nov;42(11):1145-51. Review. No abstract available.

PMID:
9534306
38.
39.

Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen.

Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT.

J Infect Dis. 1997 Jul;176(1):292-5.

PMID:
9207386
40.

Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis.

Jackson LA, Campbell LA, Schmidt RA, Kuo CC, Cappuccio AL, Lee MJ, Grayston JT.

Am J Pathol. 1997 May;150(5):1785-90.

41.

Murine models of Chlamydia pneumoniae infection and atherosclerosis.

Moazed TC, Kuo C, Grayston JT, Campbell LA.

J Infect Dis. 1997 Apr;175(4):883-90.

PMID:
9086145
42.

Prevalence of positive serology for acute Chlamydia pneumoniae infection in emergency department patients with persistent cough.

Wright SW, Edwards KM, Decker MD, Grayston JT, Wang S.

Acad Emerg Med. 1997 Mar;4(3):179-83.

43.

In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.

Kuo CC, Jackson LA, Lee A, Grayston JT.

Antimicrob Agents Chemother. 1996 Nov;40(11):2669-70.

44.

Detection of Chlamydia pneumoniae in atheroma specimens.

Jackson LA, Campbell LA, Kuo CC, Grayston JT.

J Infect Dis. 1996 Oct;174(4):893-6. No abstract available.

PMID:
8843240
45.

Future trends in Chlamydia pneumoniae research and the place of macrolides in treatment.

Grayston JT.

Clin Microbiol Infect. 1996 Mar;1 Suppl 1:S31-S37. No abstract available.

46.

Experimental rabbit models of Chlamydia pneumoniae infection.

Moazed TC, Kuo C, Patton DL, Grayston JT, Campbell LA.

Am J Pathol. 1996 Feb;148(2):667-76.

47.

Chlamydia pneumoniae and atherosclerosis.

Grayston JT.

Rev Med Interne. 1996;17 Suppl 1:45S-47S. No abstract available.

PMID:
8760682
48.

Chlamydia pneumoniae (TWAR) infection in Tanzanian children.

Aldous MB, West S, Kimaro DN, Wang S, Grayston JT, Kuo C.

Trop Doct. 1996 Jan;26(1):18-9. No abstract available.

PMID:
8693557
49.

Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery.

Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence RD, Lee MJ, Strandness ED, Wang SP.

Circulation. 1995 Dec 15;92(12):3397-400.

PMID:
8521559
50.

Chlamydia pneumoniae (TWAR).

Kuo CC, Jackson LA, Campbell LA, Grayston JT.

Clin Microbiol Rev. 1995 Oct;8(4):451-61. Review.

Supplemental Content

Loading ...
Support Center